D.A. Davidson & Co. Viking Therapeutics, Inc. Transaction History
D.A. Davidson & Co.
- $12 Billion
- Q3 2024
A detailed history of D.A. Davidson & Co. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 3,844 shares of VKTX stock, worth $125,506. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,844Holding current value
$125,506% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding VKTX
# of Institutions
476Shares Held
63.4MCall Options Held
5.76MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$332 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$197 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$153 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$69.1 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$61.2 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.5B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...